BioMarin expects $221M IPR&D charge from Inozyme acquisition, ~$1.10 EPS hit in Q3 2025

BIOMARIN PHARMACEUTICAL INC

Acquired IPR&D charge of ~$221M pre-tax from July 1 Inozyme Pharma acquisition.
Charge reduces both GAAP and Non-GAAP diluted EPS by approximately $1.10 for Q3 2025.
Q3 2025 results not finalized; actual results may differ from preliminary estimates.
BioMarin does not forecast IPR&D charges due to uncertainty of timing and magnitude.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.